The DIA conference Clinical Trial Disclosure: Towards a More Transparent World will provide guidance on potential implications of the transparency of clinical trial information in registration, reporting and more. The meeting, to be held Oct. 1 to 2 in Bethesda, Md., will bring together academics, government regulators and patient advocates to provide key guidance on:
“The continuing proliferation of national and industry-sponsored registries leaves many sponsors considering disclosure strategy, developing operational measures and looking for efficient ways to manage dissemination of clinical trial protocol information. We are excited to bring together these leaders to discuss moving the needle in clinical trial disclosures,” said Susan Cantrell, director of DIA North America.
To find out more about the event and to register, visit DIA’s website for Clinical Trial Disclosure: Towards a More Transparent World(http://www.diahome.org/en-US/Meetings-and-Training/Find-Meetings-and-Training/Meeting-Details.aspx?ProductID=2313489&EventType=Meeting).
DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C.; and Latin America. For more information, visit www.diahome.org.